Global Research Trends

Thursday 28 February 2019

Dementia Drugs Market Future Potential Of Industry 2018-2026

Dementia is one of the most prevalent neurodegenerative diseases in which patients suffer from various behavioral changes, as a primary symptoms such as decline in memory or other thinking skills and can gets worse as condition progresses. It majorly affects people of aged 65 years and above. Currently, there is no curative therapy available for dementia disease. However, drugs for dementia therapy are in pipeline, which are expected to be launched in the near future, in turn propelling growth of the dementia drugs market.

Ask For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1664

Market Dynamics

Increasing aging population along with its associated complications is the major driving factor for growth of the dementia drugs market. For instance, according to Centers of Disease Control and Prevention (CDC), 2013, five million people were suffering from AD and the number is expected to rise up to 14 million by 2050, in the U.S. Moreover, according to World Health Organization (WHO), 2017, around 47 million people suffer from dementia and around 10 million new cases are reported annually. Increasing incidence of dementia coupled with growing demand for therapy is expected to favor growth of the dementia drugs market in the near future. According to Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach to around 400,000 by 2020, and around 900,000 by 2050. Moreover, the National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to prioritize and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment, and care for dementia patients.

Increasing number of pipeline products is expected to drive growth of the dementia drugs market

Major factors fueling growth of the dementia drugs market include the large number of drugs in the pipeline, which are expected to enter into the market by 2020-2022. According to the study published by Translational Research and Clinical Intervention, in September 2017, it is recorded that 105 new drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in phase three. These new products use novel approaches such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, and serotonin 5-HT6 receptor antagonist. Furthermore, increasing collaborations amongst companies for developing drugs in joint efforts is also boosting growth of the market. For instance, in November 2017, Novartis and Amgen, along with the Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to prevent or delay symptoms of Alzheimer's disease.

Dementia Drugs Market Regional Outlook - Growing Integration of Healthcare and IT to boost demand in emerging economies

On the basis of geography, the global dementia drugs market can be segmented into six major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to hold the largest market, owing to major approval of drugs in this region and favorable reimbursement scenarios. Asia Pacific is expected to emerge as a major market in the near future, majorly due to the growing geriatric population and Alzheimer’s disease cases, especially in China, India. This in turn, is expected to create lucrative opportunities for growth of the market.

Some of the top companies operating in the dementia drugs market are Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc.., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.

Detailed Segmentation:

Global Dementia Drugs Market, By Drug Class:
- MAO Inhibitors
- Cholinesterase Inhibitors
- Glutamate Inhibitors
Global Dementia Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Global Dementia Drugs Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa

For More Information, Browse at https://www.coherentmarketinsights.com/market-insight/dementia-drugs-market-1664

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Erythromycin Market Growing At A Remarkable CAGR 2018-2026

Erythromycin is an antibiotic, which is used to treat certain kind of bacterial infections. Erythromycin topical preparations are largely used on the skin to help control acne. The antibiotic is also used in combination with other medicines and are applied topically or taken orally for treating the infections. The common side effects of erythromycin include nausea, loss of appetite, diarrhea, and abdominal pain. Erythromycin prevents bacterial cells from growing and multiplying by interfering with their ability to make proteins, while not affecting human cells. It is widely used to treat chest infections such as pneumonia, skin problems such as acne and rosacea, dental abscesses, and sexually transmitted infections.

Ask For Sample Copy at https://www.coherentmarketinsights.com/insight/request-sample/1780

Erythromycin Market Dynamics

Pharmaceutical manufacturers are focused on increasing access to affordable medications to provide novel options for patients and pharmacists, thereby addressing the limited availability of erythromycin tablets, which in turn is expected to augment market growth. For instance, in March, 2018, Amneal Pharmaceuticals received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths. The erythromycin product is a therapeutic equivalent for the reference listed drug (RLD) erythromycin tablets from Arbor Pharmaceuticals and is the only other immediate release oral tablet available. Moreover, in September 2016, ANI Pharmaceuticals, Inc. launched Erythromycin Ethylsuccinate for oral suspension 200mg/5mL indicated as a treatment for various infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires disease, pertussis, and others.

Erythromycin Market - Regional Dynamics

Regional segmentation of the global erythromycin market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America erythromycin market is expected to hold a dominant position over the forecast period, owing to rising number of regulatory approvals of drugs by regulatory agencies to address the unmet medical needs of the patients and increasing prevalence of skin and soft tissue infections. For instance, in November, 2016, Rising Pharmaceuticals, Inc.—a subsidiary of Aceto Corporation—launched Erythromycin and Benzoyl Peroxide Topical Gel USP, 3-5% an FDA-approved generic version of Valeant International’s Benzamycin Gel, 3-5%. According to the Division of Infectious Diseases, Los Angeles BioMedical Research Center, 2015, skin and soft tissue infections (SSTIs) are a common reason to seek medical care in the U.S. as they can lead to complications with significant morbidity, including hospitalization, surgical procedures, or death.

Erythromycin Market- Competitive Analysis

Key players operating in the global erythromycin market include Ani Pharmaceuticals, Akorn, Inc., Aceto Corporation, Genesis Pharmaceuticals, Teligent, Inc., Abbvie, Inc., Abbott Laboratories, Pfizer, Inc., Sanofi-Aventis, and Allergan, Plc.

Erythromycin Market Taxonomy:

On the basis of formulation, the global erythromycin market is segmented into:

Gel
Tablet
Topical Solution
Ointment
Others

On the basis of therapeutic indications, the global erythromycin market is segmented into:

Respiratory Tract Infections
Eye Infections
Ear Infections
Skin and Soft Tissue Infections
Gastro-intestinal Infections
Others

On the basis of distribution channel, the global erythromycin market is segmented into:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

On the basis of region, the global erythromycin market is segmented into:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Browse Full Report at https://www.coherentmarketinsights.com/ongoing-insight/erythromycin-market-1780

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Laser Resurfacing Devices Market Expansion To Be Persistent During 2018–2026

Laser resurfacing, also known as laser peel, laser vaporization or lasabrasion, is used for the treatment of skin problems such as acne scars and facial wrinkles. Laser resurfacing techniques direct short, concentrated beams of light at uneven skin, exactly removing skin layer by layer. The increasing inclination of people towards aesthetic appearance, especially in the urban areas, has resulted in increasing number of laser procedures, which further increases the demand for laser resurfacing devices. Physiology of wrinkled and ageing skin can be improved by aesthetic lasers and energy devices. For instance, according to the American Society for Aesthetic Plastic Surgery (ASAPS) 2016 report, over 11 million aesthetic procedures were performed by board?certified specialists, of which 16.5% were surgical procedures and 83.5% were non?surgical procedures. Laser resurfacing is of two types, namely non-ablative and ablative. Non-ablative laser resurfacing include infrared lasers, fractional laser, high impact light sources, and others. The most commonly used ablative laser resurfacing procedures include erbium laser resurfacing and CO2 laser resurfacing. Changes in lifestyle and increasing incidences related to skin treatment are driving growth of laser resurfacing devices market.

Request For Sample Copy of Research Report at https://www.coherentmarketinsights.com/insight/request-sample/1771

Laser Resurfacing Devices Market – Dynamics

The laser resurfacing devices market growth is projected to increase over the forecast period, owing to rising number of cosmetic procedures during the past decade. For instance, according to the American Society for Aesthetic Plastic Surgery (ASAPS) 2016 report, people in the U.S. spent over 15 billion dollars on combined surgical and nonsurgical procedures, in which nonsurgical procedures accounted for around 44%. The development and innovations in laser resurfacing devices allows faster healing, minimizes the time required for the procedure, and reduces the side effects, thereby driving growth of the market. Moreover, lower cost of these devices in comparison with surgeries and approval of laser devices by the U.S FDA for the treatment have propelled growth of the laser resurfacing devices market size.

Laser Resurfacing Devices Market – Regional Insights

On the basis of region, the global laser resurfacing devices market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America holds dominant position in the market, owing to rising adoption of technologically advanced devices and presence of major market players in this region, especially in the U.S. For instance, 2018 InMode Aesthetic Solutions, introduces EmbraceRF, a new facial contouring approach.

Laser Resurfacing Devices Market – Competitive Landscape

Key players operating in the global laser resurfacing devices market include Lumenis Cynosure, Inc., Alma Lasers, Altair Instruments, Cutera, Lutronic Corporation, Lynton Lasers Ltd, Syneron Medical Ltd., Sciton, Inc., and Quanta Aesthetic Lasers USA. Market players are focused towards adopting strategies such as collaborations and providing technologically advanced products to sustain their presence in the market. For instance, in 2018, SkinCeuticals and The HydraFacial Company collaborated to create a professional resurfacing protocol.

Laser Resurfacing Devices Market – Taxonomy

On the basis of type, the global laser resurfacing devices market is segmented into:

Ablative
Non-Ablative

On the basis of device, the global laser resurfacing devices market is segmented into:

Laser Skin Resurfacing Machine
CO2 Skin Laser Scanner Machine
Others

On the basis of indication, the global laser resurfacing devices market is segmented into:

Facial wrinkles
Acne scars

On the basis of end user, the global laser resurfacing devices market is segmented into:

Hospitals
Cosmetic Surgery Centers/Clinics
Multi-Specialty Centers

On the basis of geography, the global laser resurfacing devices market is segmented into:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Else Place an Enquiry Before Purchase @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2214

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Wednesday 27 February 2019

Nanopharmaceuticals Market Global Industry Insights, Size, Share, and Forecast till 2026

Global Nanopharmaceuticals Market, by Carrier Type (Liposomes, Polymer, Nanocrystals, Inorganic, Protein, and Others), by Application (Oncology, Neurology, Anti-inflammatory, Anti-infective, Cardiovascular, and Others), by End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 28,434.3 million in 2017, and is projected to exhibit a CAGR of 22.1 % over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2485

Key players in the market are focused on research and development of nanopharmaceuticals in order to develop novel products to address the critical unmet needs of patients. According to the P&T Community Journal, December 2017, DTXSPL8783, dendrimer for cancer treatment is being investigated, which is in clinical trials of phase 1 study, for patients with advanced cancer.

Similarly, Vivagel developed by Starpharma, is in phase 3 clinical trials, for bacterial vaginosis. Vivagel sale is approved in Europe and Australia. Moreover, increase in incidences of cardiovascular diseases and other diseases, is expected to boost the market growth. According to World Health Organization, factsheet 2017, around 17.9 million deaths were recorded due to cardiovascular diseases in 2016. Cardiovascular diseases was recorded as the leading cause of death, globally.

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance its product portfolio. For instance, in December 2018, Novartis acquired Endocyte, Inc., involved in developing Radioligland and other therapies for treatment of cancer. This acquisition helped Novartis to strengthen its position in cancer treatment and expand its products offering to align better healthcare.

Increasing prevalence of cardiovascular diseases, cancer, and infectious diseases are major factors driving nanopharmaceuticals market growth. The World Health Organization, factsheet September 2018, estimated around 10 million cases of tuberculosis and around 1.6 million deaths from the disease in 2017. Moreover, advantages of nanopharmaceuticals over macroscopic level medicines is expected to boost the market growth. Nanopharmaceuticals can pass the blood brain barrier and can access the remote areas of brain as well as low solubility of the compound can be developed for enhancing its characteristics.

Moreover, key players in the market are focused on receiving the U.S. Food and Drug Administration (FDA) approval for novel products to treat patients. For instance, in May 2017, NovoNodisk received Food and Drug Administration (FDA) approval for glycopegylated Rebinyn, which is used to control bleeding and bleeding management in patients diagnosed with hemophilia B.

Get Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2485

Major players operating in the global nanopharmaceuticals market include Abbott, GlaxoSmithKline plc., Eli Lilly and Company, Astrazeneca plc., Novavax, Inc., Stryker Corporation, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Tanabe Pharma Corporation, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma Inc., Navidea Biopharmaceuticals, Inc., AbbVie Inc., AMAG Pharmaceuticals, Amgen Inc., Astellas Pharma Inc., Celgene Corporation, Gilead Sciences, Inc., JOHNSON & JOHNSON, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Hoffmann-La Roche AG, Sanofi S.A, Shire Plc., and Teva Pharmaceuticals Industries Limited.

About Coherent Market Insights:

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Blepharitis Treatment Market 2018: Experts Cues For High Growth Worldwide

Blepharitis is a chronic condition that causes inflammation of the eyelids. Blepharitis usually affects the part of eyelid where eyelashes grow and occurs when tiny oil glands near this area are clogged, in turn causing irritation and redness of the eyes. Symptoms of blepharitis include high sensitivity to light, loss of eyelashes, watery eyes, burning sensation in the eyes, greasy eyelids, itchy eyes, red and swollen eyes, flaking of skin around the eyes, crusted eyelashes after waking up, more frequent blinking, abnormal growth of eyelashes, and stinging sensation in the eyes. Blepharitis causes seborrheic dermatitis, which is dandruff of the eyebrows and scalp, bacterial infection, clogged oil glands, malfunctioning of oil glands, rosacea. It also causes allergic reactions to eye medications, contact lens solutions or eye make-up and eyelash lice or mites.

Ask For In-Depth Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1761

Blepharitis Treatment Market Drivers:-

The blepharitis treatment market is expected to witness significant grow due to growing prevalence of ophthalmic disorders among the geriatric population. According to a survey conducted by American Academy of Ophthalmology in 2014, blepharitis usually affects people above the age of 50 years. It also states that blepharitis is observed in 37% male ophthalmic patients and 47% in female ophthalmic patients. Blepharitis market is also expected to grow due to increasing number of drugs in the pipeline. For instance, ISV-305 sponsored by InSite Vision is in phase 3 clinical trials, ISV-305 treats patients with early symptoms of blepharitis. Furthermore, new product launches and mergers and acquisitions over the recent past also contributes to market growth. For instance, in 2015, BlephEx, a Franklin-based company launched Rysurg. It is used to clean eyelids and also maintains hygiene. According to a study conducted by American Academy of Ophthalmology in 2015 around 50% of ophthalmic patients suffer from symptoms of blepharitis and dry eyes. Constant use of this device helps prevent recurrence of blephairis and the treatment is pain-free.

Blepharitis Treatment Market Regional Analysis:-

North America Blepharitis treatment market is expected to hold dominant position due to increasing geriatric population, launch of new products, and increasing number of ophthalmic patients in the region. According to a survey conducted in the U.S., by Population Reference Bureau in 2016, states that the aging population increased by 24% as compared to 15% in 2014. Europe is expected to witness rapid growth due to new product launches of blepharitis drugs in the region. For instance, in 2017, Scope Ophthalmic launched Moist Heat Mask, a device that helps in the treatment of blepharitis by loosening the oil present in Meibomian glands and allowing it to flow more freely. It helps to soften eye lash debris, prevent the evaporation of natural tear film, restores moisture to the eye and also the surrounding area, as well as improves tear film lipid quality.

Blepharitis Treatment Market Key Players:-

Key players operating in the Blepharitis treatment market include Scope Ophthalmic Ltd, NovaBay Pharmaceuticals Inc, Thea Pharmaceuticals Ltd, Perrigo Laboratories, InSite Vision Incorporated, Merck & Co, and Novartis AG

Blepharitis Treatment Market Taxonomy:-

The global Blepharitis treatment market is segmented based on disease type, treatment type, distribution channel, and region.

By Disease Type:-

Posterior Blepharitis
Anterior Blepharitis
Mixed Blepharitis

By Treatment Type:-

Antibiotic Therapy
Topical Corticosteroids
Topical Antibodies
Oral Antibodies
Ointments
Eye Cleansers
Others

By Distribution Channel:-

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:-

North America
Europe
Latin America
Asia-Pacific
Middle East
Africa

Browse Complete Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/blepharitis-treatment-market-1761

About Coherent Market Insights:

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Laboratory Centrifuge Equipment Market Will Continue To Grow By 2026

Laboratory centrifuge is an equipment used to separate different material from liquid medium based on their density, shape, size, and viscosity of liquid medium in which they are dissolved. Centrifuge equipment works on the principle of centrifugation, in which denser material settles at the bottom of a centrifuge tube. Centrifuge is used in various applications such as separation of cellular element such as RBC and WBC from blood sample, In hematology lab for Packed Cell Volume determination (Diagnostic Purpose majorly), removal of cellular component for microscopic study (Research Purpose), removal of protein precipitate from analytical sample, isolation of macromolecules such as DNA, RNA, and lipids from cell, and separation of solid or semisolid precipitant from analytical sample or two immiscible fluids from each other in suspension (Research Purpose). Increasing demand for multifunction, reliable and durable laboratory centrifuge equipment to conduct variety of laboratory work as mentioned above is driving growth of the laboratory centrifuge equipment market.

Download PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1231

Increasing diagnostics and research and development activities to fuel the growth of laboratory centrifuge equipment market

According to the World Health Organization (WHO) fact sheet, in 2017, 70% of deaths worldwide were due to non-communicable disease (NCD) such as cardio-vascular disease, cancer, diabetes, which is influencing pharmaceutical companies to invest more in research and development of cost-effective therapies, ultimately increasing demand for essential lab equipment such as centrifuge. According to World Economic Forum 2015 statistics, pharmaceutical companies invest majorly on research and development (Astra Zeneca tops the list with investment of 25.5% of its total revenue of financial year 2014-15). Increasing health awareness among population is propelling the growth of diagnostic market for which laboratory centrifuge equipment is essential. North America region is leading the centrifuge equipment market. According to Organization for Economic Co-operation and Development (OECD) report, North America spends 2.5% more than rest of OECD countries on health in which diagnostics holds a major share. The recent past has witnessed a significant increase in number of clinical trials for generic products (Bioequivalence safety and efficacy) due to off patenting of novel drug molecules, which in turn is increasing the demand for centrifuge equipment. There is a very positive environment even at supranational union level where group of countries coming together to achieve common development goals like health through collaborative efforts e.g. United Nations has declared Healthy lives and promoting well-being for all at all ages as its Sustainable development goal no. 3 which nations has committed to achieved by 2030 through their individual effort.

Major Players

Major players in the global laboratory centrifuge equipment market include Thermo Fisher Scientific, Eppendorf Corporation, Beckmann Coulter Inc., Hettich Lab Technology, Danaher Corporation, Hitachi Koki ltd., and Bio-Rad Laboratories.

Laboratory Centrifuge Equipment Market Taxonomy:

On the basis of rotor design:

• Fixed Angle Rotor

• Horizontal Rotor

• Vertical Rotor

On the basis of application area:

• Diagnostics

• Research and Development

On the basis configuration:

• Bench Top

• Portable

• Micro centrifuge

• Ultracentrifuge

On the basis of temperature variation facility:

• Refrigerated

• Non-Refrigerated

On the basis of speed of rotation:

• Low

• High

• Ultra

On the basis end user:

• Diagnostic laboratories

• Pharmaceutical and Biotech companies

• Research and academic places

Ask for Discount Before Purchase @ https://www.coherentmarketinsights.com/insight/request-discount/1231

About Coherent Market Insights:

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Implantable Bioartificial Kidney Market To Incur Considerable Upsurge During 2018-2026

An implantable bioartificial kidney is similar to existing extracorporeal renal assist device (RAD), which is a bioartificial kidney that combines a membrane hemofilter and a bioreactor to function as a healthy kidney. However, to work as a natural kidney, the bioartificial kidney should have high efficiency ultrafiltration membranes, should be able to regulate blood flow, and stabilize necessary cells. Implantable bioartificial kidney is capable of replicating the work of real kidney and can eliminate the need for dialysis. Implantable bioartificial kidney avoids constant physician oversight and need to take immunosuppressant drugs and medication.

Get In-Depth Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2339

Implantable Bioartificial Kidney Market: Drivers

Increasing number of chronic kidney disease patients, rising number of kidney failure incidences, and long waiting list for kidney transplants is expected to boost the global implantable bioartificial kidney market growth over the forecast period. For instance, according to Kidney Health Australia, 2010, the cost of treating all current and new cases of End Stage Kidney Disease (ESKD) will reach up to US$ 12 billion by 2020. Moreover, according to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. were estimated to have chronic kidney disease in 2017. CDC states that around 96% of the people with kidney damage or hampered kidney function are not aware of having chronic kidney disease. These factors are expected to drive the global implantable bioartificial kidney market growth over the forecast period.

Individual government organizations and manufacturers are working towards increasing the awareness of kidney diseases. For instance, American Kidney Fund (AKF) launched a comprehensive new kidney disease education portal in May 2018. The education portal called as ‘CKD Central’ will provide information and resources on chronic kidney disease (CKD). Moreover, The Kidney Project is a national research project, which aims to create a small, surgically implanted, and free-standing bioartificial kidney to treat end stage renal disease (ESRD). This kidney is expected to provide ESRD patients with a new option beyond the short-term solution of renal dialysis and the costly kidney transplant for which donor organs are limited.

Implantable Bioartificial Kidney Market: Regional Analysis

North America implantable bioartificial kidney market is expected to hold dominant position in the global market over the forecast period. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), over 661,000 people in the U.S. had kidney failure and of these, 468,000 individuals were on dialysis, in 2017. The kidney project, headed by researchers from the University of California San Francisco (UCSF), the University of Vanderbilt, and the National Institute of Biomedical Imaging and Bioengineering (NIBIB), is expected to receive approval for the artificial kidney trials by late 2018 or early 2019. These factors are expected to support the North America implantable bioartificial kidney market growth over the forecast period. According to report of Brazilian Transplant Registry, 2016, Brazil accounts for the second largest number of kidney transplant programs in the world.

Implantable Bioartificial Kidney Market: Taxonomy

The global implantable bioartificial kidney market is segmented on the basis of end user, and region.

By End User: Hospitals, Organ Transplant Centers, Others

By Region: North America, Latin America, Europe, Asia Pacific, Middle East, Africa

Request For Customization of This Business Report @ https://www.coherentmarketinsights.com/insight/request-customization/2339

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Tuesday 26 February 2019

Medicine Iontophoresis Market Analysis to 2026 Scrutinised in New Research

Iontophoresis is a technique, which uses an electric current to deliver a medicine or other chemicals through the skin. Iontophoresis is often suggested for people with hyperhidrosis (excessive sweating) of the hands and/or feet as it aids in reducing sweating. Iontophoresis is suitable for applications such as acetic acid (calcific tendinitis), calcium chloride and magnesium sulfate (control of musculoskeletal spasms), dexamethasone (inflammation), lidocaine (inflammation of soft tissues), and zinc oxide (rheumatoid arthritis).

Get In-Depth Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2248

Medicine Iontophoresis Market Drivers

Increasing awareness for treatment of hyperhidrosis is expected to drive growth of the medicine iontophoresis market. For instance, in the U.S., the International Hyperhidrosis Society (IHhS) IHhS celebrates the month of November as Hyperhidrosis Awareness Month by making documentaries, conducting interviews of patients, and organizing various events to raise awareness of hyperhidrosis among the populace. Moreover, increasing research on iontophoresis in treating various diseases and symptoms is expected to boost growth of the medicine iontophoresis market. For instance, in April 2018, EyeGate Pharma Company developed a novel ocular drug delivery system called EyeGate II iontophoresis, where an electric current generated in the device delivers ionized drug into the eye and further gets absorbed into the eye by the electric current.

Medicine Iontophoresis Market Restraints

Side effects and the limitations associated with medicine iontophoresis therapy are expected to restrain medicine iontophoresis market growth. For instance, according to British Association of Dermatologists 2016 report, people often complain symptoms of bruising or blisters incase the intensity of current is too high for iontophoresis, a sensation of mild burning in case the electrode is touched, and itchiness in the treated area after treatment. Moreover, patients with cardiac pacemakers or with metal implants are not suitable for iontophoresis treatment.

Medicine Iontophoresis Market – Regional Analysis

On the basis of region, the global medicine iontophoresis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is projected to hold dominant position in the global medicine iontophoresis market due to insurance and reimbursement strategies for treating hyperhidrosis patients. For instance, in the U.S., International Hyperhidrosis Society offers useful tools, information, and downloadable forms related to the insurance and reimbursement process. This comprises health plans for hyperhidrosis treatments, cost of therapy, medical insurance form for purchasing iontophoresis devices, and others. Such insurance and reimbursement services allow efficient treatment of hyperhidrosis.

Medicine Iontophoresis Market Competitor Analysis

Key players operating in the global medicine iontophoresis market include, ORGANIX GmbH & Co. KG, Hidrex USA, Drionic, IOMED, R.A. Fischer, Iskra Medical d.o.o., Chattanooga, Encore Medical, L.P., iTech Medical, Inc., Kimetec GmbH, and AAM.

Medicine Iontophoresis Market – Taxonomy

By Product Type:

High Frequency Devices
Low Frequency Devices

By Modality:

Tabletop
Portable

By End User:

Hospitals
Clinics
Home
Others

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2248

About Coherent Market Insights:

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Aneurysm Clips Market Will Be Fiercely Competitive in 2026

An aneurysm is the enlargement of an artery. It occurs when the walls of a blood vessel become weak, balloon out, and are more likely to rupture or leak potentially causing a stroke. The most significant aneurysms affect the arteries of the heart and the brain. Smoking and high blood pressure are the major risk factors for the development of an aneurysm. Aneurysm clipping is a crucial surgical procedure in the management of aneurysms. It is performed to block off an intact aneurysm from the blood vessels to prevent any further leaking of blood from the site.

Market Dynamics

Increasing worldwide incidences of aneurysms is the major factor driving the aneurysm clips market growth. According to the Brain Aneurysm Foundation 2018 data, around 500,000 deaths occur worldwide annually due to brain aneurysms. According to the Centers for Disease Control and Prevention (CDC), aortic aneurysms contribute to more than 25,000 deaths in the U.S. annually.

Ask For In-Depth Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2230

Aneurysms can cause due to various factors. According to the National Institute of Neurological Disorders and Stroke, factors such as alcohol and tobacco consumption and drug abuse are expected to increase the risks of aneurysms development. According to the Tobacco Atlas, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria from 2015 to 2025. This rise in tobacco consumption is expected to grow aneurysm cases eventually driving the aneurysm clips market growth. However, being an invasive surgery, clipping procedure can increase the duration of recovery period and patient hospital stay eventually increasing the overall treatment cost.

Increasing incidences of aneurysm is expected to drive the aneurysm clips market growth

Although brain aneurysms affect individuals of all age, it is most prevalent in people age between 35 and 60. According to the Brain Aneurysm Foundation 2018 data, brain aneurysms cause nearly 500,000 deaths worldwide annually with half the victims younger than 50 years. Various factors contributing to the formation of brain aneurysms include smoking, drug use such as cocaine, hypertension or high blood pressure, congenital resulting from inborn abnormality in artery wall, tumors, traumatic head injury, family history of brain aneurysms and other disorders such as Polycystic Kidney Disease, Ehlers-Danlos Syndrome, Marfan Syndrome, and Fibromuscular Dysplasia (FMD).

Aneurysm Clips Market - Regional Insights

On the basis of region, the global aneurysm clips market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America aneurysm clips market is expected to foresee major revenue share, owing to increasing incidences of aneurysm in the U.S. According to the Brain Aneurysm Foundation 2018 data, around six million people in the U.S. have unruptured aneurysms.

Aneurysm Clips Market - Key Players

Key players operating in the global aneurysm clips market include B. Braun, Boston Scientific, Codman & Shurtleff, Integra LifeSciences, InoMed, KLS Martin Group, Medtronic Plc., Mizuho America, St. Jude Medical, Stryker Corporation, and RauMedic.

Detailed Segmentation:

Global Aneurysm Clips Market, By Aneurysm Type:

Abdominal Aneurysm
Cerebral Aneurysm
Thoracic Aneurysm
Peripheral Aneurysm

Global Aneurysm Clips Market, By Raw Material:

Titanium
Cobalt
Others

Global Aneurysm Clips Market, By Region:

North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Browse Complete Research Report @ https://www.coherentmarketinsights.com/market-insight/aneurysm-clips-market-2230

About Coherent Market Insights:

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Skull Clamp Market Adopts Innovation to Stay Competitive Forecast 2026

Most neurosurgery procedures need rigid fixation of the head for successful operation. Skull clamps are indicated for such use in case of percutaneous craniotomies and spinal surgeries. They are placed on patient’s skull to hold their neck and head in proper posture during surgeries. Increasing number of neurosurgeries and development of new surgical techniques have led to demand for miniaturized instruments such as skull clamps to reduce post-surgical scars on body.

Skull Clamp Market – Drivers

Advancements in skull clamp technologies is expected to boost growth of the market. For instance, in October 2017, Mizuho OSI, a leading manufacturer of surgical equipment in the U.S., launched a new technology called Levo Head Positioning System at North American Spine Society (NASS), which will provide accurate head positioning during spine surgeries. It has various interchangeable modules, which supports efficient attachment to skull clamps providing safe and efficient patient care.

Ask for In-Depth Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2226

Skull Clamp Market – Regional Analysis

On the basis of region, the global skull clamp market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the skull clamp market, owing to increasing geriatric populations and increasing cases of brain injuries. For instance, according to a report published in The Morbidity and Mortality Weekly Report (MMWR) 2017, in the U.S., 153 people die due to traumatic brain injuries every day.

Asia Pacific is also expected to witness significant growth in the skull clamp market due to continuous foreign investments and less cost of spinal surgeries. For instance, according to data released by India Brand Equity Foundation on September 2018, healthcare has become one of India’s largest sectors both in terms of revenue and employment, and the cost of surgery in India is about one-tenth of that in the U.S. or Western Europe. Moreover, according to data released by the Department of Industrial Policy and Promotion (DIPP) 2018, the healthcare sector of India attracted Foreign Direct Investment (FDI) worth US$ 5.25 billion between April 2000 and June 2018.

Key players operating in the global skull clamp market include;

1. Allen Medical Systems, Inc.

2. Barrfab

3. Eschmann Equipment

4. Medifa - Hesse GmbH & Co. KG

5. Schaerer Medical

6. TECHNOMED INDIA.

7. OPT SURGISYSTEMS S.R.L.

8. Micromar Ind. e Com. LTDA

9. pro med instruments, Inc.

10. Herbert

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2226

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com